Real world data of lisocabtagene maraleucel in Japanese patients with relapsed or refractory large B-cell lymphoma

Real world data of lisocabtagene maraleucel in Japanese patients with relapsed or refractory large B-cell lymphoma - JSCT CART23

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048958

Enrollment

100

Registered

2023-01-01

Start date

2023-05-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B-cell lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients who underwent Liso-cel treatment 2.Patients undergoing Liso-cel treatment 3. Aged 18 or older at the time of obtaining consent 4. Consent to participate in this study has been obtained from the principal investigator of the patient referral institution

Exclusion criteria

Exclusion criteria: If the doctor in charge determines that it is inappropriate to participate in this study

Design outcomes

Primary

Measure	Time frame
Overall survival after CAR T cell infusion	—

Countries

Japan

Contacts

Public Contacttoyohiro kawano

JSCT office

jsct-office@umin.ac.jp042-505-4251

Outcome results